Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or off-the-shelf, cell therapies for serious ophthalmic and neurological diseases. It uses a proprietary pluripotent-cell platform, AlloSCOPE, to design, manufacture, and test specialized human cells intended to replace or support damaged tissue, often through collaborations with larger pharmaceutical partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead therapeutic candidates in human trials for ophthalmic and neurological diseases.
Earlier-stage programs being advanced through internal development or partnerships.
Revenue from research, development, and license collaborations with partners such as Roche.
Cell engineering, banking, formulation, and cGMP production capabilities used across programs.
Products
Reported · share of revenue- Event Based Milestones and Other Collaborative Revenue49.2 %
- Upfront License Fees44.3 %
- Royalties License and Other Revenues6.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Lineage Cell Therapeutics sells primarily to pharmaceutical and biotech collaborators rather than end patients, with Roche/Genentech being the most visible partner in its lead program. Its therapies are ultimately aimed at patients with geographic atrophy, spinal cord injury, and auditory neuropathy, but near-term value creation comes from licensing, collaboration, and development milestones. Government agencies have also supported some programs through grants.
Buy development rights, access to assets, and platform expertise to advance cell therapy programs.
Partner on preclinical or early clinical assets where shared development reduces risk and cost.
Provide non-dilutive funding for research and development of selected programs.
The eventual end users of the therapies, especially in ophthalmology and neurology.
Strategy
Lineage’s strategy is to use its AlloSCOPE platform to create a pipeline of related allogeneic cell therapy assets that can be advanced internally or partnered. The company is prioritizing programs with clear clinical and commercial potential, while using collaborations to share development cost, broaden expertise, and improve the odds of success. It also emphasizes scalable manufacturing, since reproducibility and supply are central to any future commercialization.
The lead ophthalmology program is the most advanced asset and a key source of validation.
Reliable, reproducible cell production is essential for clinical supply and eventual commercialization.
Additional collaborations can fund development and increase the value of the platform.
Geography
2025The company is headquartered in the United States, but its development footprint is international through collaborations and operations tied to partners and facilities abroad. The reports specifically note facilities in Israel and a worldwide collaboration with Roche, which makes the business exposed to cross-border regulatory, operational, and geopolitical risks. Because it is still clinical-stage, geography matters more for where trials, manufacturing, and partner activity occur than for commercial sales.
Risks
The company faces the classic risks of clinical-stage biotech: uncertain trial outcomes, regulatory delay, and dependence on third-party partners for development and commercialization. Its cell-therapy model adds manufacturing and supply-chain complexity, including the risk that cell lines, delivery devices, or infectious contamination issues could disrupt programs or force costly remediation. Geopolitical and personnel risks are also meaningful because operations include facilities in Israel and the business depends on specialized scientific talent.
- Clinical development failureImpact: HighLikelihood: Medium
Programs are still in early-stage testing and may not demonstrate sufficient safety or efficacy.
Exposure - Manufacturing and cell-bank contaminationImpact: HighLikelihood: Medium
Allogeneic cell therapies depend on stable cell lines and reproducible cGMP production.
Exposure: Foundational cell lines and cell banks
- Regulatory uncertainty for novel cell therapiesImpact: HighLikelihood: Medium
There is limited precedent for pluripotent stem cell-derived and iPSC-derived approvals.
Exposure: FDA and other major markets
- Third-party device and supply dependenceImpact: MediumLikelihood: Medium
Specialized delivery systems may be needed and could be unavailable or fail performance standards.
Exposure: Administration tools and devices
- Geopolitical disruption in IsraelImpact: MediumLikelihood: Low
Facilities and employees in Israel may be affected by regional conflict and mobilization.
Exposure: Israel operations
Accounting
Judgemental itemsMilestones and performance obligations can shift revenue between periods.
Impact: Affects reported revenue timing and comparability
Clinical-stage assets may need write-downs if prospects weaken.
Impact: Can materially affect earnings and balance sheet value
Judgment is required at issuance and remeasurement may be needed.
Impact: Can create non-cash gains or losses
Valuation allowances and uncertain tax positions depend on estimates.
Impact: Affects tax expense and net loss
Similar listed companies
Publicly listed companies with a comparable business focus.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Design Therapeutics, Inc.
DSGN · Pharmaceutical Preparations
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® molecules, a small-molecule platform designed to target the underlying…
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
Brainstorm Cell Therapeutics Inc.
BCLI · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026